Replay available

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call

Fate Therapeutics, Inc. (NASDAQ: FATE) Q4 2023 earnings conference call, held 2024-02-26. Replay captured from the company's public earnings webcast.

Mon, February 26, 2024 at 5:00 PMendedReplay
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Scott Washko

President and CEO

Ed Duloc

Chief Financial Officer

Dr. Bob Valimer

Chief Research and Development Officer

Michael Yee

Analyst, Jefferies

Yigal Nekomovich

Analyst, Citigroup

Tara Bancroft

Analyst, TD Cohen

Tazeen Ahmad

Analyst, Bank of America

Dinah Graybosh

Analyst, Lurink Partners

Mike Ohls

Analyst, Morgan Stanley

Peter Lawson

Analyst, Barclays

Carolina Alvarez

Analyst, Stiefel (on behalf of Ben Burnett)

Talani Usman

Analyst, Goldman Sachs (on behalf of Andrea Tan)

Yanan Zhu

Analyst, Wells Fargo Securities

Replay transcript excerpt

Welcome to the Faith Therapeutics fourth quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. This call is being webcast live on the investors section of Faith's website at faiththerapeutics.com. As a reminder, today's call is being recorded. I would now like to introduce Scott Washko, president and CEO of Faith Therapeutics. Thank you. Good afternoon and thanks everyone for joining us for the Faith Therapeutics fourth quarter 2023 financial results call. Shortly after 4 p.m. Eastern time today, we issued a press release with these results, which can be found on the investor section of our website under press releases. In addition, our form 10K for the year ended December 31, 2023 was filed shortly thereafter and can be found on the Investors section of our website under Financial Information. Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statement disclaimer on the company's earnings press release issued after the close of market today, as well as the risk factors included in our Form 10-K for the year ended December 31, 2023 that was filed with the SEC today. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made, as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, Fait...

More from Fate Therapeutics, Inc.